Alzheimer's Disease - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：1,242頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Alzheimer's Disease - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 11
Alzheimer's Disease Overview 12
Therapeutics Development 13
Alzheimer's Disease - Therapeutics under Development by Companies 15
Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 34
Alzheimer's Disease - Pipeline Products Glance 43
Alzheimer's Disease - Products under Development by Companies 47
Alzheimer's Disease - Products under Investigation by Universities/Institutes 76
Alzheimer's Disease - Companies Involved in Therapeutics Development 86
Alzheimer's Disease - Therapeutics Assessment 293
Drug Profiles 325
Alzheimer's Disease - Recent Pipeline Updates 1023
Alzheimer's Disease - Dormant Projects 1142
Alzheimer's Disease - Discontinued Products 1165
Alzheimer's Disease - Product Development Milestones 1174
Appendix 1181
List of Tables
Number of Products under Development for Alzheimer's Disease, H1 2014 73
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2014 74
Number of Products under Development by Companies, H1 2014 76
Number of Products under Development by Companies, H1 2014 (Contd..1) 77
Number of Products under Development by Companies, H1 2014 (Contd..2) 78
Number of Products under Development by Companies, H1 2014 (Contd..3) 79
Number of Products under Development by Companies, H1 2014 (Contd..4) 80
Number of Products under Development by Companies, H1 2014 (Contd..5) 81
Number of Products under Development by Companies, H1 2014 (Contd..6) 82
Number of Products under Development by Companies, H1 2014 (Contd..7) 83
Number of Products under Development by Companies, H1 2014 (Contd..8) 84
Number of Products under Development by Companies, H1 2014 (Contd..9) 85
Number of Products under Development by Companies, H1 2014 (Contd..10) 86
Number of Products under Development by Companies, H1 2014 (Contd..11) 87
Number of Products under Development by Companies, H1 2014 (Contd..12) 88
Number of Products under Development by Companies, H1 2014 (Contd..13) 89
Number of Products under Development by Companies, H1 2014 (Contd..14) 90
Number of Products under Development by Companies, H1 2014 (Contd..15) 91
Number of Products under Development by Companies, H1 2014 (Contd..16) 92
Number of Products under Development by Companies, H1 2014 (Contd..17) 93
Number of Products under Investigation by Universities/Institutes, H1 2014 95
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 98
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 99
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 100
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 101
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 102
Comparative Analysis by Late Stage Development, H1 2014 103
Comparative Analysis by Clinical Stage Development, H1 2014 104
Comparative Analysis by Early Stage Development, H1 2014 105
Comparative Analysis by Unknown Stage Development, H1 2014 106
Products under Development by Companies, H1 2014 107
Products under Development by Companies, H1 2014 (Contd..1) 108
Products under Development by Companies, H1 2014 (Contd..2) 109
Products under Development by Companies, H1 2014 (Contd..3) 110
Products under Development by Companies, H1 2014 (Contd..4) 111
Products under Development by Companies, H1 2014 (Contd..5) 112
Products under Development by Companies, H1 2014 (Contd..6) 113
Products under Development by Companies, H1 2014 (Contd..7) 114
Products under Development by Companies, H1 2014 (Contd..8) 115
Products under Development by Companies, H1 2014 (Contd..9) 116
Products under Development by Companies, H1 2014 (Contd..10) 117
Products under Development by Companies, H1 2014 (Contd..11) 118
Products under Development by Companies, H1 2014 (Contd..12) 119
Products under Development by Companies, H1 2014 (Contd..13) 120
Products under Development by Companies, H1 2014 (Contd..14) 121
Products under Development by Companies, H1 2014 (Contd..15) 122
Products under Development by Companies, H1 2014 (Contd..16) 123
Products under Development by Companies, H1 2014 (Contd..17) 124
Products under Development by Companies, H1 2014 (Contd..18) 125
Products under Development by Companies, H1 2014 (Contd..19) 126
Products under Development by Companies, H1 2014 (Contd..20) 127
Products under Development by Companies, H1 2014 (Contd..21) 128
Products under Development by Companies, H1 2014 (Contd..22) 129
Products under Development by Companies, H1 2014 (Contd..23) 130
Products under Development by Companies, H1 2014 (Contd..24) 131
Products under Development by Companies, H1 2014 (Contd..25) 132
Products under Development by Companies, H1 2014 (Contd..26) 133
Products under Development by Companies, H1 2014 (Contd..27) 134
Products under Development by Companies, H1 2014 (Contd..28) 135
Products under Investigation by Universities/Institutes, H1 2014 136
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 137
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 138
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 139
Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 140
Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 141
Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 142
Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 143
Products under Investigation by Universities/Institutes, H1 2014 (Contd..8) 144
Products under Investigation by Universities/Institutes, H1 2014 (Contd..9) 145
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 146
Alzheimer's Disease - Pipeline by Johnson & Johnson, H1 2014 147
Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 148
Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 149
Alzheimer's Disease - Pipeline by Biogen Idec Inc., H1 2014 150
Alzheimer's Disease - Pipeline by OXIS International, Inc., H1 2014 151
Alzheimer's Disease - Pipeline by Shionogi & Co., Ltd., H1 2014 152
Alzheimer's Disease - Pipeline by NsGene A/S, H1 2014 153
Alzheimer's Disease - Pipeline by Amgen Inc., H1 2014 154
Alzheimer's Disease - Pipeline by Sanofi, H1 2014 155
Alzheimer's Disease - Pipeline by AstraZeneca PLC, H1 2014 156
Alzheimer's Disease - Pipeline by Eli Lilly and Company, H1 2014 157
Alzheimer's Disease - Pipeline by Perrigo Company, H1 2014 158
Alzheimer's Disease - Pipeline by GlaxoSmithKline plc, H1 2014 159
Alzheimer's Disease - Pipeline by Genentech, Inc., H1 2014 160
Alzheimer's Disease - Pipeline by MedImmune, LLC, H1 2014 161
Alzheimer's Disease - Pipeline by Merck & Co., Inc., H1 2014 162
Alzheimer's Disease - Pipeline by United Biomedical, Inc., H1 2014 163
Alzheimer's Disease - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 164
Alzheimer's Disease - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 165
Alzheimer's Disease - Pipeline by Euroscreen S.A., H1 2014 166
Alzheimer's Disease - Pipeline by Applied NeuroSolutions, Inc., H1 2014 167
Alzheimer's Disease - Pipeline by Sangamo BioSciences, Inc., H1 2014 168
Alzheimer's Disease - Pipeline by NeuroDerm Ltd., H1 2014 170
Alzheimer's Disease - Pipeline by Plexxikon Inc., H1 2014 171
Alzheimer's Disease - Pipeline by Biotherapix SLU, H1 2014 172
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2014 173
Alzheimer's Disease - Pipeline by Panacea Pharmaceuticals, Inc., H1 2014 174
Alzheimer's Disease - Pipeline by Nanotherapeutics, Inc., H1 2014 175
Alzheimer's Disease - Pipeline by Novartis AG, H1 2014 176
Alzheimer's Disease - Pipeline by Aphios Corporation, H1 2014 177
Alzheimer's Disease - Pipeline by Alzhyme Ltd., H1 2014 178
Alzheimer's Disease - Pipeline by EnVivo Pharmaceuticals, H1 2014 179
Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H1 2014 180
Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 181
Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2014 182
Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H1 2014 183
Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 184
Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS, H1 2014 185
Alzheimer's Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 186
Alzheimer's Disease - Pipeline by Octapharma AG, H1 2014 187
Alzheimer's Disease - Pipeline by Orion Oyj, H1 2014 188
Alzheimer's Disease - Pipeline by Pain Therapeutics, Inc., H1 2014 189
Alzheimer's Disease - Pipeline by Pfizer Inc., H1 2014 190
Alzheimer's Disease - Pipeline by SK Chemicals Co., Ltd., H1 2014 191
Alzheimer's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 192
Alzheimer's Disease - Pipeline by Toyama Chemical Co., Ltd., H1 2014 193
Alzheimer's Disease - Pipeline by Vivus, Inc., H1 2014 194
Alzheimer's Disease - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 195
Alzheimer's Disease - Pipeline by Addex Therapeutics, H1 2014 196
Alzheimer's Disease - Pipeline by Evotec AG, H1 2014 197
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H1 2014 198
Alzheimer's Disease - Pipeline by Neuralstem, Inc., H1 2014 199
Alzheimer's Disease - Pipeline by Genfit SA, H1 2014 200
Alzheimer's Disease - Pipeline by Avanir Pharmaceuticals, Inc., H1 2014 201
Alzheimer's Disease - Pipeline by Lupin Limited, H1 2014 202
Alzheimer's Disease - Pipeline by Bionomics Limited, H1 2014 203
Alzheimer's Disease - Pipeline by ReGenX Biosciences, LLC, H1 2014 204
Alzheimer's Disease - Pipeline by Nymox Pharmaceutical Corporation, H1 2014 205
Alzheimer's Disease - Pipeline by Paladin Labs Inc., H1 2014 206
Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H1 2014 207
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 208
Alzheimer's Disease - Pipeline by Oligomerix, inc., H1 2014 209
Alzheimer's Disease - Pipeline by ProteoTech, Inc., H1 2014 210
Alzheimer's Disease - Pipeline by Prana Biotechnology Limited, H1 2014 211
Alzheimer's Disease - Pipeline by Xenetic Biosciences plc, H1 2014 212
Alzheimer's Disease - Pipeline by Biotie Therapies Corp., H1 2014 213
Alzheimer's Disease - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 214
Alzheimer's Disease - Pipeline by Theravance, Inc., H1 2014 215
Alzheimer's Disease - Pipeline by Resverlogix Corp., H1 2014 216
Alzheimer's Disease - Pipeline by Suven Life Sciences Ltd., H1 2014 217
Alzheimer's Disease - Pipeline by Summit Corporation plc, H1 2014 218
Alzheimer's Disease - Pipeline by CrystalGenomics, Inc., H1 2014 219
Alzheimer's Disease - Pipeline by Mithridion, Inc., H1 2014 220
Alzheimer's Disease - Pipeline by Teikoku Pharma USA, Inc., H1 2014 221
Alzheimer's Disease - Pipeline by tesa Labtec GmbH, H1 2014 222
Alzheimer's Disease - Pipeline by Eisai Ltd., H1 2014 223
Alzheimer's Disease - Pipeline by Oryzon Genomics S.A., H1 2014 224
Alzheimer's Disease - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 225
Alzheimer's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2014 226
Alzheimer's Disease - Pipeline by CoMentis, Inc., H1 2014 227
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2014 228
Alzheimer's Disease - Pipeline by Humanetics Corporation, H1 2014 229
Alzheimer's Disease - Pipeline by Accera, Inc., H1 2014 230
Alzheimer's Disease - Pipeline by Sonexa Therapeutics, Inc., H1 2014 231
Alzheimer's Disease - Pipeline by D-Pharm Ltd., H1 2014 232
Alzheimer's Disease - Pipeline by StemCells, Inc., H1 2014 233
Alzheimer's Disease - Pipeline by Proteome Sciences Plc, H1 2014 234
Alzheimer's Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 235
Alzheimer's Disease - Pipeline by Probiodrug AG, H1 2014 236
Alzheimer's Disease - Pipeline by Snowdon Inc., H1 2014 237
Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H1 2014 238
List of Figures
Number of Products under Development for Alzheimer's Disease, H1 2014 73
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2014 74
Number of Products under Development by Companies, H1 2014 75
Number of Products under Investigation by Universities/Institutes, H1 2014 94
Comparative Analysis by Late Stage Development, H1 2014 103
Comparative Analysis by Clinical Stage Development, H1 2014 104
Comparative Analysis by Early Stage Products, H1 2014 105
Assessment by Monotherapy Products, H1 2014 353
Assessment by Combination Products, H1 2014 354
Number of Products by Top 10 Target, H1 2014 355
Number of Products by Stage and Top 10 Target, H1 2014 356
Number of Products by Top 10 Mechanism of Action, H1 2014 367
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 368
Number of Products by Top 10 Route of Administration, H1 2014 379
Number of Products by Stage and Top 10 Route of Administration, H1 2014 380
Number of Products by Top 10 Molecule Type, H1 2014 382
Number of Products by Stage and Top 10 Molecule Type, H1 2014 383
Table of Contents 2
Introduction 11
Alzheimer's Disease Overview 12
Therapeutics Development 13
Alzheimer's Disease - Therapeutics under Development by Companies 15
Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 34
Alzheimer's Disease - Pipeline Products Glance 43
Alzheimer's Disease - Products under Development by Companies 47
Alzheimer's Disease - Products under Investigation by Universities/Institutes 76
Alzheimer's Disease - Companies Involved in Therapeutics Development 86
Alzheimer's Disease - Therapeutics Assessment 293
Drug Profiles 325
Alzheimer's Disease - Recent Pipeline Updates 1023
Alzheimer's Disease - Dormant Projects 1142
Alzheimer's Disease - Discontinued Products 1165
Alzheimer's Disease - Product Development Milestones 1174
Appendix 1181
List of Tables
Number of Products under Development for Alzheimer's Disease, H1 2014 73
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2014 74
Number of Products under Development by Companies, H1 2014 76
Number of Products under Development by Companies, H1 2014 (Contd..1) 77
Number of Products under Development by Companies, H1 2014 (Contd..2) 78
Number of Products under Development by Companies, H1 2014 (Contd..3) 79
Number of Products under Development by Companies, H1 2014 (Contd..4) 80
Number of Products under Development by Companies, H1 2014 (Contd..5) 81
Number of Products under Development by Companies, H1 2014 (Contd..6) 82
Number of Products under Development by Companies, H1 2014 (Contd..7) 83
Number of Products under Development by Companies, H1 2014 (Contd..8) 84
Number of Products under Development by Companies, H1 2014 (Contd..9) 85
Number of Products under Development by Companies, H1 2014 (Contd..10) 86
Number of Products under Development by Companies, H1 2014 (Contd..11) 87
Number of Products under Development by Companies, H1 2014 (Contd..12) 88
Number of Products under Development by Companies, H1 2014 (Contd..13) 89
Number of Products under Development by Companies, H1 2014 (Contd..14) 90
Number of Products under Development by Companies, H1 2014 (Contd..15) 91
Number of Products under Development by Companies, H1 2014 (Contd..16) 92
Number of Products under Development by Companies, H1 2014 (Contd..17) 93
Number of Products under Investigation by Universities/Institutes, H1 2014 95
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 98
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 99
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 100
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 101
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 102
Comparative Analysis by Late Stage Development, H1 2014 103
Comparative Analysis by Clinical Stage Development, H1 2014 104
Comparative Analysis by Early Stage Development, H1 2014 105
Comparative Analysis by Unknown Stage Development, H1 2014 106
Products under Development by Companies, H1 2014 107
Products under Development by Companies, H1 2014 (Contd..1) 108
Products under Development by Companies, H1 2014 (Contd..2) 109
Products under Development by Companies, H1 2014 (Contd..3) 110
Products under Development by Companies, H1 2014 (Contd..4) 111
Products under Development by Companies, H1 2014 (Contd..5) 112
Products under Development by Companies, H1 2014 (Contd..6) 113
Products under Development by Companies, H1 2014 (Contd..7) 114
Products under Development by Companies, H1 2014 (Contd..8) 115
Products under Development by Companies, H1 2014 (Contd..9) 116
Products under Development by Companies, H1 2014 (Contd..10) 117
Products under Development by Companies, H1 2014 (Contd..11) 118
Products under Development by Companies, H1 2014 (Contd..12) 119
Products under Development by Companies, H1 2014 (Contd..13) 120
Products under Development by Companies, H1 2014 (Contd..14) 121
Products under Development by Companies, H1 2014 (Contd..15) 122
Products under Development by Companies, H1 2014 (Contd..16) 123
Products under Development by Companies, H1 2014 (Contd..17) 124
Products under Development by Companies, H1 2014 (Contd..18) 125
Products under Development by Companies, H1 2014 (Contd..19) 126
Products under Development by Companies, H1 2014 (Contd..20) 127
Products under Development by Companies, H1 2014 (Contd..21) 128
Products under Development by Companies, H1 2014 (Contd..22) 129
Products under Development by Companies, H1 2014 (Contd..23) 130
Products under Development by Companies, H1 2014 (Contd..24) 131
Products under Development by Companies, H1 2014 (Contd..25) 132
Products under Development by Companies, H1 2014 (Contd..26) 133
Products under Development by Companies, H1 2014 (Contd..27) 134
Products under Development by Companies, H1 2014 (Contd..28) 135
Products under Investigation by Universities/Institutes, H1 2014 136
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 137
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 138
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 139
Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 140
Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 141
Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 142
Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 143
Products under Investigation by Universities/Institutes, H1 2014 (Contd..8) 144
Products under Investigation by Universities/Institutes, H1 2014 (Contd..9) 145
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 146
Alzheimer's Disease - Pipeline by Johnson & Johnson, H1 2014 147
Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 148
Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 149
Alzheimer's Disease - Pipeline by Biogen Idec Inc., H1 2014 150
Alzheimer's Disease - Pipeline by OXIS International, Inc., H1 2014 151
Alzheimer's Disease - Pipeline by Shionogi & Co., Ltd., H1 2014 152
Alzheimer's Disease - Pipeline by NsGene A/S, H1 2014 153
Alzheimer's Disease - Pipeline by Amgen Inc., H1 2014 154
Alzheimer's Disease - Pipeline by Sanofi, H1 2014 155
Alzheimer's Disease - Pipeline by AstraZeneca PLC, H1 2014 156
Alzheimer's Disease - Pipeline by Eli Lilly and Company, H1 2014 157
Alzheimer's Disease - Pipeline by Perrigo Company, H1 2014 158
Alzheimer's Disease - Pipeline by GlaxoSmithKline plc, H1 2014 159
Alzheimer's Disease - Pipeline by Genentech, Inc., H1 2014 160
Alzheimer's Disease - Pipeline by MedImmune, LLC, H1 2014 161
Alzheimer's Disease - Pipeline by Merck & Co., Inc., H1 2014 162
Alzheimer's Disease - Pipeline by United Biomedical, Inc., H1 2014 163
Alzheimer's Disease - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 164
Alzheimer's Disease - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 165
Alzheimer's Disease - Pipeline by Euroscreen S.A., H1 2014 166
Alzheimer's Disease - Pipeline by Applied NeuroSolutions, Inc., H1 2014 167
Alzheimer's Disease - Pipeline by Sangamo BioSciences, Inc., H1 2014 168
Alzheimer's Disease - Pipeline by NeuroDerm Ltd., H1 2014 170
Alzheimer's Disease - Pipeline by Plexxikon Inc., H1 2014 171
Alzheimer's Disease - Pipeline by Biotherapix SLU, H1 2014 172
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2014 173
Alzheimer's Disease - Pipeline by Panacea Pharmaceuticals, Inc., H1 2014 174
Alzheimer's Disease - Pipeline by Nanotherapeutics, Inc., H1 2014 175
Alzheimer's Disease - Pipeline by Novartis AG, H1 2014 176
Alzheimer's Disease - Pipeline by Aphios Corporation, H1 2014 177
Alzheimer's Disease - Pipeline by Alzhyme Ltd., H1 2014 178
Alzheimer's Disease - Pipeline by EnVivo Pharmaceuticals, H1 2014 179
Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H1 2014 180
Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 181
Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2014 182
Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H1 2014 183
Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 184
Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS, H1 2014 185
Alzheimer's Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 186
Alzheimer's Disease - Pipeline by Octapharma AG, H1 2014 187
Alzheimer's Disease - Pipeline by Orion Oyj, H1 2014 188
Alzheimer's Disease - Pipeline by Pain Therapeutics, Inc., H1 2014 189
Alzheimer's Disease - Pipeline by Pfizer Inc., H1 2014 190
Alzheimer's Disease - Pipeline by SK Chemicals Co., Ltd., H1 2014 191
Alzheimer's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 192
Alzheimer's Disease - Pipeline by Toyama Chemical Co., Ltd., H1 2014 193
Alzheimer's Disease - Pipeline by Vivus, Inc., H1 2014 194
Alzheimer's Disease - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 195
Alzheimer's Disease - Pipeline by Addex Therapeutics, H1 2014 196
Alzheimer's Disease - Pipeline by Evotec AG, H1 2014 197
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H1 2014 198
Alzheimer's Disease - Pipeline by Neuralstem, Inc., H1 2014 199
Alzheimer's Disease - Pipeline by Genfit SA, H1 2014 200
Alzheimer's Disease - Pipeline by Avanir Pharmaceuticals, Inc., H1 2014 201
Alzheimer's Disease - Pipeline by Lupin Limited, H1 2014 202
Alzheimer's Disease - Pipeline by Bionomics Limited, H1 2014 203
Alzheimer's Disease - Pipeline by ReGenX Biosciences, LLC, H1 2014 204
Alzheimer's Disease - Pipeline by Nymox Pharmaceutical Corporation, H1 2014 205
Alzheimer's Disease - Pipeline by Paladin Labs Inc., H1 2014 206
Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H1 2014 207
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 208
Alzheimer's Disease - Pipeline by Oligomerix, inc., H1 2014 209
Alzheimer's Disease - Pipeline by ProteoTech, Inc., H1 2014 210
Alzheimer's Disease - Pipeline by Prana Biotechnology Limited, H1 2014 211
Alzheimer's Disease - Pipeline by Xenetic Biosciences plc, H1 2014 212
Alzheimer's Disease - Pipeline by Biotie Therapies Corp., H1 2014 213
Alzheimer's Disease - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 214
Alzheimer's Disease - Pipeline by Theravance, Inc., H1 2014 215
Alzheimer's Disease - Pipeline by Resverlogix Corp., H1 2014 216
Alzheimer's Disease - Pipeline by Suven Life Sciences Ltd., H1 2014 217
Alzheimer's Disease - Pipeline by Summit Corporation plc, H1 2014 218
Alzheimer's Disease - Pipeline by CrystalGenomics, Inc., H1 2014 219
Alzheimer's Disease - Pipeline by Mithridion, Inc., H1 2014 220
Alzheimer's Disease - Pipeline by Teikoku Pharma USA, Inc., H1 2014 221
Alzheimer's Disease - Pipeline by tesa Labtec GmbH, H1 2014 222
Alzheimer's Disease - Pipeline by Eisai Ltd., H1 2014 223
Alzheimer's Disease - Pipeline by Oryzon Genomics S.A., H1 2014 224
Alzheimer's Disease - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 225
Alzheimer's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2014 226
Alzheimer's Disease - Pipeline by CoMentis, Inc., H1 2014 227
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2014 228
Alzheimer's Disease - Pipeline by Humanetics Corporation, H1 2014 229
Alzheimer's Disease - Pipeline by Accera, Inc., H1 2014 230
Alzheimer's Disease - Pipeline by Sonexa Therapeutics, Inc., H1 2014 231
Alzheimer's Disease - Pipeline by D-Pharm Ltd., H1 2014 232
Alzheimer's Disease - Pipeline by StemCells, Inc., H1 2014 233
Alzheimer's Disease - Pipeline by Proteome Sciences Plc, H1 2014 234
Alzheimer's Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 235
Alzheimer's Disease - Pipeline by Probiodrug AG, H1 2014 236
Alzheimer's Disease - Pipeline by Snowdon Inc., H1 2014 237
Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H1 2014 238
List of Figures
Number of Products under Development for Alzheimer's Disease, H1 2014 73
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2014 74
Number of Products under Development by Companies, H1 2014 75
Number of Products under Investigation by Universities/Institutes, H1 2014 94
Comparative Analysis by Late Stage Development, H1 2014 103
Comparative Analysis by Clinical Stage Development, H1 2014 104
Comparative Analysis by Early Stage Products, H1 2014 105
Assessment by Monotherapy Products, H1 2014 353
Assessment by Combination Products, H1 2014 354
Number of Products by Top 10 Target, H1 2014 355
Number of Products by Stage and Top 10 Target, H1 2014 356
Number of Products by Top 10 Mechanism of Action, H1 2014 367
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 368
Number of Products by Top 10 Route of Administration, H1 2014 379
Number of Products by Stage and Top 10 Route of Administration, H1 2014 380
Number of Products by Top 10 Molecule Type, H1 2014 382
Number of Products by Stage and Top 10 Molecule Type, H1 2014 383
